Cancer Active Immunotherapy

I would like to thank all my co-workers who have collaborated with me, from 1963 until now, in biological and clinical research in the field of cancer active immunotherapy, of its immuno­ prevention and immunorestoration. They will often be quoted in this book. I am particularly grateful to those who have helped me to write it by reviewing some chapters: D. BELPOMME, J. F. DOR~, IRENE FLORENTIN, A. GOUTNER, I. J. Hm, R. HUCHET and MARIE-CHRISTINE SIMMLER. I also thank NICOLE VRIZ, MARIE-CLAUDE S